Shop by category
Growth Hormone Axis ResearchRegeneration ResearchPeptide BioregulatorsCognitive & Neuropeptide ResearchMetabolic & Cellular ResearchMelanocortin & Endocrine ResearchDermal Peptide ResearchImmune & Thymic ResearchKhavinson bioregulators are peptides 2 to 4 amino acids long. The research program led by Vladimir Khavinson developed them at the St. Petersburg Institute of Bioregulation and Gerontology. They are studied as tissue-specific regulators of gene expression and as candidate geroprotectors, meaning compounds studied for slowing age-related change. Our Peptide Bioregulators category page discusses them further.
This article explains the proposed mechanism of direct peptide-DNA interaction. It also covers the immune and telomerase-related findings reported in current preclinical literature. Everything below is an in vitro or animal finding. These compounds are still being investigated for the effects described here. The proposed mechanisms below are hypotheses, studied largely by one research program. Nothing below is a statement on outcomes in people.
The first work used substances called cytomedins. These were low molecular weight substances isolated from animal tissue extracts, with peptide-like activity. More defined synthetic peptides came next, intended to reproduce the activity of the substances identified from those tissue extracts. The original peptide identification methods used are not equivalent to current peptide sequencing and identification standards.
Thymalin was the first preparation, a polypeptide complex from calf thymus. The synthetic series that followed includes Epitalon (Ala-Glu-Asp-Gly), the pineal peptide most associated with the program. It also includes Pinealon (Glu-Asp-Arg) and Testagen (Lys-Glu-Asp-Gly). Two more in the series are Vilon (Lys-Glu), the two-amino-acid immune peptide, and Pancragen (Lys-Glu-Asp-Trp), the four-amino-acid pancreatic peptide. Other compounds in the series are labeled by organ, including Bronchogen (bronchial), Cardiogen (cardiac), Cartalax (cartilage), and Vesugen (vascular).
The originating research group proposes that each peptide preferentially influences the tissue its parent extract came from. Independent studies of tissue specificity and cross-reactivity would be needed to validate this claim more broadly.
The central and most distinctive proposal is that these peptides can cross cell membranes and interact directly with DNA in a sequence-selective way. Sequence-selective means picking out particular stretches of DNA rather than binding anywhere along it. That interaction is proposed to alter gene expression without engaging conventional cell-surface receptors.
Fedoreyeva and colleagues reported an in vitro study in 2011. They tagged short peptides, including Epitalon, Pinealon, and Testagen, with a fluorescent label. Those peptides penetrated into the nucleus of cultured HeLa cells, a human cell line grown in the laboratory.
The team also ran cell-free tests. They measured fluorescence quenching for each peptide against a panel of single- and double-stranded oligonucleotides, meaning short strands of nucleic acid. The values differed depending on which strand a peptide was tested against, and those differences tracked each peptide's own sequence. The peptides also distinguished between different nucleotide sequences, including whether their cytosine bases carried a methyl group.[3]
The authors interpreted this as evidence that short peptides can in principle reach and bind nucleic acids.
Khavinson and colleagues reported a separate study in 2014. It looked at a four-amino-acid peptide from bronchial tissue, studied under the designation Bronchogen.
The peptide altered expression of a panel of genes involved in the identity of the cells lining the airways, measured by real-time PCR. It also interacted with DNA in vitro, as assessed by spectrophotometry, viscometry, and circular dichroism.[4] Further investigation in other tissue types would be needed to establish how broadly this applies.
Findings of this kind are cell-level. They do not by themselves demonstrate organ function changes in a living animal. This should be read as a proposed mechanism supported by in vitro data, not as an established pathway.
Khavinson and colleagues reported an in vitro study in 2003. They used cultures of human fetal fibroblasts with no telomerase activity of their own. Telomerase is the enzyme that lengthens telomeres, the caps on the ends of chromosomes.
Adding Epitalon induced expression of the telomerase catalytic subunit, the enzyme's working part. It also induced telomerase activity and telomere elongation.[1] This finding is based on cultured human cells rather than living people. The study compared cultures in the presence or absence of the peptide, applied as a single dose.
Anisimov and colleagues reported an animal study in 2003 in female outbred Swiss-derived SHR mice. The mice were given monthly courses of subcutaneous Epitalon from three months of age until natural death.
The results were mixed. In these mice, Epitalon treatment:
The authors read this pattern as geroprotector activity. The absence of any mean-lifespan effect is nonetheless a useful check on broader claims made elsewhere.
Across the wider series, the program's own review literature attributes immune normalization to thymic preparations such as Thymalin in animal models. That literature also reports that long-term treatment with some preparations increased mean life span by twenty to forty percent in rodents.[5] Both claims come from the same research group that developed these compounds, and the sections below return to that.
These peptides are studied within a specific framework, the hypothesis that declining synthesis of the body's own regulatory peptides drives aging. It further holds that supplying short peptides can restore gene expression and slow age-related change.
Anisimov and Khavinson summarized this framework in a 2010 review. It presents decades of rodent lifespan, biomarker, and tumor-incidence data alongside long-term human clinical observations.[5]
The framework is coherent and has generated a substantial body of work, though it is based largely on studies from within the originating group. It should be understood as one specific theory within aging research, and one that awaits reproduction by independent laboratories.
The most important caveat concerns where this research comes from. The great majority of it originates from the Khavinson program and its collaborators, and that includes nearly all of the direct-DNA-interaction mechanism work. Independent replication in other laboratories has been limited.
The proposed sequence-selective DNA binding is not a broadly validated mechanism in mainstream molecular biology. Reported effects also sometimes vary between studies, as the mouse lifespan result illustrates. Reported peptide sequences for several compounds differ across sources as well, which complicates comparison.
The Khavinson bioregulators are a series of very short, synthetic peptides studied under a distinctive hypothesis. That hypothesis is that they act through direct, sequence-selective interaction with DNA to regulate gene expression. This action is proposed to underlie a geroprotector effect.
The supporting data are preclinical. They span in vitro tests of nuclear penetration and gene expression, plus animal studies with mixed results. They remain concentrated within a single research program.
The evidence above describes what has been investigated, not what any individual should expect. Researchers interested in this series can find the full Peptide Bioregulators research category alongside batch-specific documentation for each compound.
Not in the findings this article covers, which are in vitro or animal only. The telomerase result is based on cultured human cells rather than living subjects, and the lifespan result on female outbred Swiss-derived SHR mice. The 2010 review is described as presenting decades of rodent lifespan, biomarker, and tumor-incidence data alongside long-term human clinical observations, but none of those human observations are reported here. Nothing in this article is a statement on outcomes in people.
Independent replication in other laboratories has been limited. The great majority of this research, and nearly all of the direct-DNA-interaction mechanism work, originates from the Khavinson program and its collaborators. The proposed sequence-selective DNA binding is not a broadly validated mechanism in mainstream molecular biology, and reported effects sometimes vary between studies, as the mouse lifespan result illustrates. It should be read as a proposed mechanism supported by in vitro data, not as an established pathway.
Reported peptide sequences for several compounds differ across sources, which complicates comparison. This article does not explain why they differ. It does note separately that the original peptide identification methods used are not equivalent to current peptide sequencing and identification standards.
References
Almost everything in pharmacology starts by binding a receptor. The claim made for these peptides is that they skip that step and reach the gene itself.
The names record the organ each compound's original extract came from, and that origin is also the series' central scientific claim.
Vesilute is a trade name for the dipeptide Glu-Asp. The one indexed animal study found no difference from its amino acids on the three endpoints it measured.
An evidence-led look at Vilon research: how independent the literature is, animal findings including an adverse one, and a computational DNA mechanism.
An evidence-led look at Vesugen research: identity and naming, its presence inside four other products, and two uncontrolled human reports.
An evidence-led look at Thymalin research: what the preparation actually is, the COVID-19 trial, the older human literature, and what is unproven.
An evidence-led look at Testagen research: what the compound is, the entire published literature, and the questions that remain unstudied.
An evidence-led look at Prostamax research: a safety signal in its clearest result, identity as a defined peptide not an extract, and what is untested.
